Cathy Duong

Cathy Duong

Auto-generated profile, based on publicly available information

Cathy Duong

Cancer Research Laboratory, Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, Oregon

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
PKPrasad R. Kopparapu
Prasad R. Kopparapu
MPMartin C. Pearce
Martin C. Pearce
CLChristiane Loehr
Christiane Loehr
CDCathy Duong
Cathy Duong
HJHyo Sang Jang
Hyo Sang Jang
SKSiva Kolluri
Siva Kolluri
Cancer cells exploit the expression of anti-apoptotic protein Bcl-2 to evade apoptosis and develop resistance to therapeutics. High levels of Bcl-2 leads to sequestration of pro-apoptotic proteins causing the apoptotic machinery to halt. In this study, we report discovery of a small molecule, BFC1108 (5-chloro-N-(2-ethoxyphenyl)-2-[(4-methoxybenzyol)amino]benzamide), which targets Bcl-2 and converts it into a pro-apoptotic protein. The apoptotic effect of BFC1108 is not inhibited, but rather potentiated, by Bcl-2 overexpression. BFC1108 induces a conformational change in Bcl-2, resulting in the exposure of its BH3 domain both in vitro and in vivo. BFC1108 suppresses the growth of triple-negative breast cancer xenografts with high Bcl-2 expression and inhibits breast cancer lung metastasis. This study demonstrates a novel approach to targeting Bcl-2 using BFC1108, a small molecule Bcl-2 functional converter that effectively induces apoptosis in Bcl-2–expressing cancers. Significance: We report the identification of a small molecule that exposes the Bcl-2 killer conformation and induces death in Bcl-2–expressing cancer cells. Selective targeting of Bcl-2 and elimination of cancer cells expressing Bcl-2 opens up new therapeutic avenues.

4 March 2024
Verified
Other
Open access
PKPrasad R. Kopparapu
Prasad R. Kopparapu
MPMartin C. Pearce
Martin C. Pearce
CLChristiane Loehr
Christiane Loehr
CDCathy Duong
Cathy Duong
HJHyo Sang Jang
Hyo Sang Jang
SKSiva Kolluri
Siva Kolluri
Cancer cells exploit the expression of anti-apoptotic protein Bcl-2 to evade apoptosis and develop resistance to therapeutics. High levels of Bcl-2 leads to sequestration of pro-apoptotic proteins causing the apoptotic machinery to halt. In this study, we report discovery of a small molecule, BFC1108 (5-chloro-N-(2-ethoxyphenyl)-2-[(4-methoxybenzyol)amino]benzamide), which targets Bcl-2 and converts it into a pro-apoptotic protein. The apoptotic effect of BFC1108 is not inhibited, but rather potentiated, by Bcl-2 overexpression. BFC1108 induces a conformational change in Bcl-2, resulting in the exposure of its BH3 domain both in vitro and in vivo. BFC1108 suppresses the growth of triple-negative breast cancer xenografts with high Bcl-2 expression and inhibits breast cancer lung metastasis. This study demonstrates a novel approach to targeting Bcl-2 using BFC1108, a small molecule Bcl-2 functional converter that effectively induces apoptosis in Bcl-2–expressing cancers.Significance:We report the identification of a small molecule that exposes the Bcl-2 killer conformation and induces death in Bcl-2–expressing cancer cells. Selective targeting of Bcl-2 and elimination of cancer cells expressing Bcl-2 opens up new therapeutic avenues.

4 March 2024
Verified
Other
Open access
PKPrasad R. Kopparapu
Prasad R. Kopparapu
MPMartin C. Pearce
Martin C. Pearce
CLChristiane Loehr
Christiane Loehr
CDCathy Duong
Cathy Duong
HJHyo Sang Jang
Hyo Sang Jang
SKSiva Kolluri
Siva Kolluri
BFC1108 suppresses viability of multiple cancer cell types. A, Bcl-2–selective inhibition of clonogenic survival of MDA-MB-231 cells. MDA-MB-231/Vector and MDA-MB-231/Bcl-2 cells were exposed to 10 µmol/L concentration in medium containing 10% FBS for 48 hours and the colony formation was determined after 2 weeks. B, Quantification of colony formation data shown in A. ***, P < 0.001. C, Bcl-2–dependent induction of apoptosis by BFC1108. MDA-MB-231 cells with high or low Bcl-2 expression were treated with 10 µmol/L BFC1108 in a medium containing 10% FBS for 48 hours and apoptosis was determined by annexin V staining. Data from one representative experiment is shown. Refer to Supplementary Fig. S1 for additional independent experiments. D, BFC1108 inhibits viability of breast cancer cells with Bcl-2 expression. The indicated breast cancer cells were treated for 48 hours, and viability was measured using CellTiter-Glo assay. Data were analyzed by two-way ANOVA and Dunnett multiple comparison post hoc test, **, P < 0.001; ****, P < 0.00001. Bottom panel indicates Bcl-2 RMA-normalized mRNA expression from the Cancer Cell Line Encyclopedia (50). E, BFC1108 suppresses viability of multiple cancer cell types with minimal effects on MCF10A nontransformed breast epithelial cells. Cells were treated for 48 hours in 10% serum containing medium and cell viability was determined. ***, P < 0.001.

4 March 2024
Verified
Other
Open access
PKPrasad R. Kopparapu
Prasad R. Kopparapu
MPMartin C. Pearce
Martin C. Pearce
CLChristiane Loehr
Christiane Loehr
CDCathy Duong
Cathy Duong
HJHyo Sang Jang
Hyo Sang Jang
SKSiva Kolluri
Siva Kolluri
BFC1108 induces cell death across multiple Bcl-2–expressing TNBC cell lines to a greater extent than ABT199. Cell death percentage is calculated based upon viability assay after 72 hours treatment at the indicated BFC1108 concentrations.

4 March 2024
Verified
Other
Open access
PKPrasad R. Kopparapu
Prasad R. Kopparapu
MPMartin C. Pearce
Martin C. Pearce
CLChristiane Loehr
Christiane Loehr
CDCathy Duong
Cathy Duong
HJHyo Sang Jang
Hyo Sang Jang
SKSiva Kolluri
Siva Kolluri
BFC1108 activates intrinsic mitochondrial death pathway. A, BFC1108 suppresses the colony-forming ability of MEF cells in a Bcl-2–dependent manner. WT and Bcl-2−/− MEF cells were treated for 48 hours in a medium containing 10% FBS and the colony formation was determined after 2 weeks. B, Quantification of colony formation data shown in A. **, P < 0.01. C, Bax or Bak is required for BFC1108-induced suppression of viability. WT MEF, Bax Knockout (Bax−/− Bak+/+), Bak knockout (Bax+/+ Bak−/−) and double knockout (Bax−/− Bak−/−) MEF cells were treated with 1 µmol/L BFC1108 for 24 hours in 10% FBS medium and viability was assessed using CellTiter-Glo assay. **, P < 0.01; ***, P < 0.001; ns, not significant. D, BFC1108 decreases mitochondrial membrane potential of Bcl-2–expressing H460 lung cancer cells. JC-1 dye was used to stain live H460 cells that were treated with 10 µmol/L BFC1108 for 16 hours in 10% FBS containing medium. Images taken with FITC, and rhodamine filters were overlaid. Cells stained orange have intact mitochondrial outer membrane and the ones turning green have compromised outer membrane indicating loss of membrane potential.

4 March 2024
Verified
Other
Open access
PDF file
PKPrasad R. Kopparapu
Prasad R. Kopparapu
MPMartin C. Pearce
Martin C. Pearce
CLChristiane Loehr
Christiane Loehr
CDCathy Duong
Cathy Duong
HJHyo Sang Jang
Hyo Sang Jang
SKSiva Kolluri
Siva Kolluri
Bcl-2 dependent apoptotic effects of BFC1108. Independent experimental replicates of data in Figure 2C are shown.